{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125374","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.872282+00:00","generated_at":"2026-05-30T01:54:50.343743+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenon Q3 2024 net loss $62.8M; X-TOLE2 topline data expected H2 2025; COO appointed","bullets":["Net loss of $62.8M for Q3 2024, compared to $48.5M in Q3 2023; R&D expenses rose to $57.0M.","Cash and marketable securities $803.3M as of Sep 30, 2024; cash runway expected into 2027.","Phase 3 X-TOLE2 focal onset seizure study topline data anticipated in H2 2025.","Phase 3 MDD study X-NOVA2 expected to initiate by end of 2024.","Appointed Matt Ronsheim as COO, new senior executive; early-stage pipeline targeting multiple INDs in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125374","json":"https://secwatch.observer/filing/0000950170-24-125374.json","markdown":"https://secwatch.observer/filing/0000950170-24-125374.md","text":"https://secwatch.observer/filing/0000950170-24-125374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024125374/0000950170-24-125374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024125374/xene-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:54:50.343743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}